<DOC>
	<DOC>NCT01434277</DOC>
	<brief_summary>This study is to evaluate the safety of a new preservative in a lubricant eye drop used four times a day in healthy adults and subjects diagnosed with dry eye.</brief_summary>
	<brief_title>Safety Evaluation of a New Preservative in a Lubricating Eye Drop</brief_title>
	<detailed_description>Single-site, open-labeled study. Twenty two subjects will be enrolled into the healthy adult group and twenty two subjects into the dry eye group. Each subject will be in the study for approximately 2 weeks (treatment) and seen at three study Visits: Visit 1 (Day 0, Baseline), Visit 2 (Day 7 +/- 1) and Visit 3 (Day 14 +/- 1). Dosing regimen is 1-2 drops into each eye, four times daily, for two weeks. Assessments will be comprised of visual acuity, slit lamp biomicroscopy, fluorescein corneal staining, and product comfort.</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>At least 18 years of age Able to follow all study instructions and attend all required study visits Provide written informed consent Visual health and eye comfort within protocolspecified parameters Women of childbearing potential must have a negative urine pregnancy test at screening, not be breastfeeding, and agree to use a protocolspecified acceptable form of birth control throughout the study Any medical condition or history, or ocular scores, or use of any drug, device or medication that, per protocol or in the opinion of the investigator, might compromise the safety of the subject or analysis of the study results. Use of contact lenses outside protocol allowance Selfreported pregnancy, positive urine pregnancy test, breastfeeding; intends to become pregnant or breastfeed during the duration of the study, refuses protocolspecified urine pregnancy testing, and/or does not use protocolspecified birth control methods and agree to continue doing so for the duration of the study. Participated in an investigational drug or device trial within 30 days of entering the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Preservative</keyword>
	<keyword>Eye Drops</keyword>
</DOC>